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Transcription factors Myf5 and MyoD are critical for myoblast determination. Myogenin is a direct transcriptional target
of these factors and its expression is associated with commitment to terminal differentiation. Here, we have used myogenic
derivatives of human U20S cells expressing Myf5 or MyoD under control of a tetracycline-sensitive promoter to study
expression of endogenous myogenin (myf4). We find that Myf5-mediated induction of myogenin shows striking dependence
on cell density. At high cell density, Myf5 is a potent inducer of myogenin expression. At low cell density, Myf5 (unlike
MyoD) is a poor inducer of myogenin expression, whilst retaining the capacity to direct expression of other muscle-specific
genes. The permissive influence of high cell density on myogenin induction by Myf5 is not a consequence of serum
depletion or cell cycle arrest, but is mimicked by a disruption adjacent to the basic region of Myf5 (Myf5/mt) which reduces
its DNA binding affinity for E-boxes without compromising its ability to transactivate a reporter gene driven by the
myogenin promoter. Coculture of cells expressing wild-type Myf5 and Myf5/mt leads to reduced myogenin induction in
Myf5/mt cells. We propose that at low cell density Myf5 inhibits induction of myogenin. © 2001 Elsevier Science
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The MRFs are muscle-specific basic helix–loop–helix
(bHLH) transcription factors which play essential roles in
determination and differentiation of skeletal muscle cells
both in vivo and in ex vivo models (Yun and Wold, 1996).
MyoD, the founding member of the family, was identified
through its capacity to induce a myogenic phenotype in
C3H 10T1/2 fibroblasts (Davis et al., 1987). This property of
“myogenic conversion” is shared by all four members of the
MRF family (MyoD, myogenin, Myf5, MRF4) (Braun et al.,
1989b; Davis et al., 1987; Miner and Wold, 1990; Rhodes
and Konieczny, 1989; Wright et al., 1989), and is presumed
to rely on transactivation of muscle-specific promoters
through direct binding to E-box motifs present in those
promoters (Weintraub et al., 1991), although recruitment by
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574DNA-bound MEF2 transcription factor also occurs (Ed-
mondson et al., 1992; Molkentin et al., 1995).
Despite their shared ability to direct myogenic conver-
sion, the four MRFs play distinct roles both in vivo and in
ex vivo myogenic systems, although it remains unclear to
what extent this is a consequence of their differing expres-
sion profiles during development/differentiation and to
what extent a consequence of intrinsic functional differ-
ences between them. In vivo, expression of either Myf5 or
MyoD (“early” MRF) is required for the existence of a pool
of determined myoblast precursor cells (Rudnicki et al.,
1993). Expression of myogenin (“late” MRF) is required for
these precursor cells to undergo differentiation (Hasty et al.,
1993; Nabeshima et al., 1993). In the most frequently
studied in vitro system of muscle differentiation, the C2
muscle cell line (Yaffe´ and Saxel, 1977), MyoD and Myf5 are
both expressed in proliferating myoblast cells (Lindon et al.,
1998). The appearance of myogenin—and loss of Myf5
expression—is associated with cell cycle withdrawal and
the onset of terminal differentiation (Andre´s and Walsh,
1996; Lindon et al., 1998; Mangiacapra et al., 1992). Myo-
genin is a direct transcriptional target of MyoD (Hollenberg
et al., 1993), which can remodel the chromatin structure of
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575Cell Density-Dependent Induction of myf4the myogenin locus (Gerber et al., 1997), and there is
evidence that Myf5 can fulfil a similar role (Buchberger et
al., 1994; Gerber et al., 1997).
Muscle-specific transactivation functions of MyoD are
repressed in proliferating cells by mechanisms which in-
clude direct interaction with repressive partners cdk4
(Zhang et al., 1999a, and references therein) and HDAC1
(Mal et al., 2001). Myf5 does not interact with cdk4 (Zhang
et al., 1999a) and it is not known how its activity is
regulated in proliferating cells. We have previously shown
that Myf5 undergoes accelerated proteolysis during mitosis
(Lindon et al., 1998). To study the myogenic properties of
MyoD and Myf5, we have stably introduced either of these
genes under the control of a tetracycline-regulatable pro-
moter into the myogenically convertible human U20S cell
line. In contrast to previous results obtained in C3H 10T1/2
fibroblast cells (for examples, see Aurade´ et al., 1994; Braun
et al., 1989a), we find that MyoD is not induced by the
overexpression of Myf5 in these cells, which thus represent
a unique system to study the functions of Myf5 in the
absence of MyoD activity. Unexpectedly, we find that, in
these cells, under conditions where Myf5 is fully able to
activate transcription of certain endogenous muscle-
specific promoters, it acts as a poor inducer of the endoge-
nous myogenin (myf4; Braun et al., 1989a) gene. We show
that Myf5 is in fact able to induce myogenin expression in
these cells only at high cell density, or upon mutation of the
putative D-box motif, close to the DNA-binding bHLH
region of Myf5, which reduces its DNA binding affinity but
does not affect its ability to transactivate a reporter gene
driven by the myogenin promoter in transient transfection
assays. We show that the weak permissiveness of low cell
density for myogenin induction by Myf5 occurs at least in
part through a non-cell-autonomous inhibition.
MATERIALS AND METHODS
Cell Culture
UTA6-Myf5 cells have been described previously (Lindon et al.,
2000). UTA6-MyoD cells were isolated after stable transfection of
UTA6 cells with pUHD10–3MyoD, constructed using a mouse
MyoD cDNA which was the gift of H. Weintraub. UTA6 cells and
clones derived from these cells, were passaged as described in
Lindon et al. (2000). The following clones were used in the
experiments illustrated: Fig. 1, Clones A2 (Myf5/wt) and M2
(MyoD); Fig. 2, A2 and R5 (Myf5/R93A,L96A); Fig. 3, A2 and R5;
Fig. 4A, A2 and R5; Fig. 4B, A2, A5, R4, and R5; Fig. 5, A2 and R5.
Seeding densities, serum conditions, and tetracycline withdrawal
protocols were as described in the text and in figure legends.
C3H 10T1/2 cells and C2.C7 cells were cultured in a 1:1 mixture
of DME/MCDB 202 media containing 10% foetal calf serum (FCS)
or 20% FCS, respectively.
Stable cell lines in which Myf5 expression is under control of
ecdysone were derived from C2.C7 cells by using vectors pIND and
pVgRXR (Invitrogen, Groningen, the Netherlands) as described by
the manufacturer. Clones were selected in 500 mg/ml G418 (Sigma
Chemical Co., St. Louis, MO) and 20 mg/ml bleocin (Calbiochem,
La Jolla, CA). Cells shown in Fig. 6 were cultured for 3 days in the
© 2001 Elsevier Science. Apresence of 20% FCS and no hormone, then cultured for a further
4 days in the presence of 1 mM ponasterone A (Invitrogen).
RNA Blot Analysis
RNA blots were prepared, using 10 mg of total RNA from each
sample, as previously described (Pinset et al., 1988). Probes were
prepared by random priming of cDNA fragments:
255 bp human Myf5 cDNA fragment (NcoI–SphI, 91% homology
with mouse sequence) from pEMSV-hmyf5 (Braun et al., 1989b).
600 bp human MyoD cDNA fragment (from first codon to MluI
site, 89% homology with equivalent mouse sequence) generated by
RT-PCR from human skeletal muscle mRNA (Clontech Laborato-
ries Inc.).
350 bp human myogenin cDNA fragment obtained by RT-PCR
on human skeletal muscle RNA (Clontech Laboratories, Inc.) using
primers specific to the first exon of the mouse myogenin gene.
Immunocytochemical Analyses
Cultured cells were fixed, permeabilized, stained, and mounted
essentially as described previously (Lindon et al., 1998). Primary
antibodies were mouse monoclonal anti-Troponin T (clones JLT-
12; Sigma Chemical Co.) used at 1:100, mouse monoclonal anti-
myogenin (clone F5D; Dr. W. Wright, University of Texas, Dallas,
TX) used at 1:40, rabbit polyclonal antibody raised against the
C-terminal peptide of Myf5 (Lindon et al., 1998), whole serum used
at 1:1000. Secondary antibodies used were goat anti-rabbit coupled
to Alexa 488 (Molecular Probes Inc., Eugene, OR) or goat anti-
mouse coupled to biotin (Sigma Chemical Co.) followed by
streptavidin-coupled Alexa594 (Molecular Probes, Inc.).
Immunoblot Analysis
Whole-cell extracts were processed for immunoblot analysis as
described previously (Lindon et al., 1998). Primary antibodies
described in the previous section were used at the following
dilutions: anti-troponin T (1:50), anti-myogenin (1:10), and anti-
Myf5 (1:1000).
Bivariate Analysis by Flow Cytometry
Cells were harvested and fixed in 70% ethanol as previously
described (Lindon et al., 1998). Immunocytochemical detection of
myogenin was carried out as described in Juan and Darzynkiewicz
(1998), using primary antibody (F5D) diluted 1:10 and secondary
antibody (Alexa488-coupled goat anti-mouse) at 1:50. Cells were
then treated with RNase A and propidium iodide as previously
described (Lindon et al., 1998) and analysed for green (530 nm) and
red (.620 nm) fluorescence on a FACStar flow cytometer (Beckton
Dickinson Co., Mountain View, CA).
Transfection and Reporter Gene Assays
Transfections were carried out by using Fugene6 transfection
reagent (Roche Diagnostics Ltd) according to the manufacturers’
instructions. Chloramphenicol acetyltransferase (CAT) activity
was assayed by chromatography of reaction products (as described
in Albagli-Curiel et al., 1993); b-galactosidase and luciferase activi-
ties by standard protocols (see Dhordain et al., 1997).
ll rights reserved.
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Myf5 Does Not Induce Myogenin Efficiently in
U20S Cells
We have previously described cell lines established from
a human osteosarcoma (U20S)-derived clone, UTA6 (Eng-
lert et al., 1995), in which the expression of Myf5 is
regulated by tetracycline (Lindon et al., 2000). Additionally,
we established UTA6 cell lines expressing MyoD, in order
to compare the functions of the two MRFs under similar
experimental conditions. U20S cells have previously been
shown to undergo myogenic conversion in response to
FIG. 1. Myogenin is poorly induced in U20S cells expressing M
UTA6-MyoD and UTA6-Myf5 cell populations cultured for 5 da
Troponin T or myogenin and costained with DAPI. Antibodies are
markers are overwhelmingly found to be expressed in mononucle
myogenic system. (B) RNA blot analysis of total cellular RNA from
days (8 days) in the presence (1tet) or absence of tetracycline. Pro
Materials and Methods. S26 ribosomal protein cDNA probe was us
the relative expression levels of Myf5 and MyoD, we note that h
specific activities and a similar degree of homology to their targetMyoD overexpression (Gu et al., 1993). We have found that
© 2001 Elsevier Science. AMyoD and Myf5 both induce “phenotypic conversion” in
these cells, as measured by the expression of structural
marker genes such as Troponin T, skeletal muscle-specific
Myosin Light Chain and Myosin Heavy Chain isoforms
(Lindon et al., 2000). The extent of myogenic conversion
triggered by overexpression of MyoD or Myf5 in U20S cells
appears broadly similar (Fig. 1A, Troponin T stainings). In
addition, we did not detect any cross-activation between
Myf5 and MyoD in this cell model (Fig. 1B), which thus
permits the study of the distinct properties of these MRFs.
Examination of the expression of myogenic markers in
clones expressing MyoD or Myf5, (typically, by immunocy-
(A) Immunocytochemical analysis of representative fields from
the absence of tetracycline, examined for expression of either
ibed in Materials and Methods. We note that these differentiation
cells, cell fusion and myotube formation being rare events in this
A6-MyoD and UTA6-Myf5 cells, cultured for 3 days (3 days) or 8
r human myogenin, Myf5, and MyoD sequences are described in
the loading control. Although we are not able to compare directly
izations to the corresponding transcripts, using probes of similar
ences, give similar signal intensities.yf5.
ys in
descr
ated
UT
bes fo
ed as
ybridtochemical analysis of cells plated at 103–104 cells/cm2 and
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577Cell Density-Dependent Induction of myf4FIG. 2. Myogenin induction in Myf5-expressing cells is cell density-dependent. (A) Immunocytochemical analysis of myogenin expression in
UTA6-Myf5 cells grown for 4 days in the absence of tetracycline after seeding at low density (4 3 103 cells/cm2) or high density (4 3 104
cells/cm2). The percentage (mean plus standard deviation) of myogenin-positive cells in each population is indicated to the right of the figure:
These were obtained by averaging the percentage of myogenin positive cells across 10 randomly chosen fields, counting at least 2 dishes in each
of 3 independent experiments. (B) Immunoblot analysis of extracts prepared from UTA6-Myf5 cells grown at high cell density (H) or low cell
density (L), as in (A). Cells were cultured in 10% FCS (10%), 1% FCS (1%), or were refed with 10% FCS on a daily basis (RF). After blotting,
extracts were examined for the presence of myogenin, Troponin T, and Myf5. (C, D) Cell cycle distribution of myogenin-expressing
cells. UTA6-Myf5 cells seeded at 8 3 103 cells/cm and cultured for 4 days in the presence or absence of tetracycline were fixed and
stained with anti-myogenin antibody and propidium iodide as described in Materials and Methods. (C) Bivariate FACS analysis
showing myogenin-associated fluorescence (vertical axis) against propidium iodide fluorescence (DNA content, horizontal axis). G1
and G2/M subpopulations staining positive for myogenin were calculated as 9.6 and 13.9% of the total number of cells in G1 and G2/M,
respectively. (D) Bivariate FACS analysis of UTA6-Myf5/mt cells cultured for 4 days in the absence of tetracycline.
FIG. 3. Myogenin is efficiently induced at low cell density by a mutant version of Myf5. UTA6-Myf5 (UTA6-Myf5/wt) and
UTA6-Myf5/R93A, L96A (UTA6-Myf5/mt) cells cultured for 4 days in the absence of tetracycline and analysed for myogenin expression
by immunocytochemistry. The percentage of myogenin-positive cells in each population is indicated: This figure was derived by averaging
the percentage of myogenin-positive cells in 10 randomly selected fields from each of 2 dishes in 4 independent experiments.
© 2001 Elsevier Science. All rights reserved.
578 Lindon et al.induced for 3–4 days) revealed that, whereas myogenin/
myf4 (hereafter referred to as myogenin) is clearly induced
as a consequence of MyoD overexpression, there was no
significant induction of myogenin in Myf5-expressing U20S
cells (Fig. 1A). We verified that this result was produced by
several clones expressing each protein, and corresponds to a
difference in myogenin mRNA level in the presence of the
different factors. Indeed, the myogenin transcript is abun-
dant in UTA6-MyoD cells 3 days after induction, but
indetectable in RNA from UTA6-Myf5 cells at this time
point (Fig. 1B).
Thus, under these conditions, both MyoD and Myf5
induce myogenic conversion, but MyoD appears as a much
more efficient activator of myogenin gene expression than
Myf5.
Induction of Myogenin by Myf5 in U20S Cells Is
Cell Density-Dependent
Forced expression of any MRF activates expression of the
endogenous myogenin gene in the model fibroblast cell line
C3H 10T1/2 (Aurade´ et al., 1994; Braun et al., 1989a).
Moreover, the myogenin promoter in 10T1/2 cells has been
demonstrated to be a direct target of MyoD (Gerber et al.,
1997; Hollenberg et al., 1993) and of Myf5 (Buchberger et
al., 1994). Thus, we tested conditions under which myoge-
nin might be induced more efficiently in UTA6-Myf5 cell
lines.
The low-level accumulation of myogenin transcripts
which we observed after prolonged Myf5 induction (Fig. 1B)
suggested that either increasing cell density or serum de-
privation might favour myogenin expression in response to
Myf5. We tested these parameters, by immunofluorescence
and immunoblot analyses (Figs. 2A and 2B). We found that
cells plated at high density (4 3 104/cm2) expressed myoge-
nin with far higher frequency than at the usual cell densi-
ties with which we work (4 3 103/cm2). Representative
fields from one such experiment are shown in Fig. 2A. We
consistently found a 6- to 10-fold increase in the proportion
of cells scoring positive for myogenin expression at the
higher cell density (Fig. 2A). Immunoblot analysis con-
firmed that myogenin expression is indeed density-
dependent in these cell populations (Fig. 2B). By contrast,
low serum conditions did not appear to favour expression of
myogenin (Fig. 2B), whereas these conditions—known to
favour differentiation—dramatically increase expression of
Troponin T (Fig. 2B). We additionally carried out daily
refeeding of high density cultures with fresh serum (10%) to
test whether this could block the induction of myogenin
seen at high cell density. We saw no reduction in myogenin
expression under these conditions, which did however lead
to reduced expression of Troponin T (Fig. 2B). Therefore, the
induction of myogenin by Myf5 is independent of depletion
of serum components.
We also confirmed that myogenin expression in these
cells does not correlate with G arrest, by simultaneous1
analysis of myogenin and DNA content of UTA6-Myf5
© 2001 Elsevier Science. Acells after 4 days’ induction in order to assess the distribu-
tion of myogenin-positive cells in the cell cycle. The
bivariate distribution of cell populations stained for myo-
genin expression reveals that myogenin-positive cells are
not restricted to the G1 subpopulation (Fig. 2C). Moreover,
whilst testing different derivatives of Myf5 (Lindon et al.,
2000), we found that a version of Myf5 bearing a double
point mutation adjacent to the DNA-binding domain
(Myf5/R93A,L96A) is an efficient inducer of myogenin
expression (Fig. 2D and see below) whilst impaired in its
ability to trigger growth arrest. Thus, myogenin induction
by Myf5 does not correlate with growth arrest in G1, both in
agreement with our observation that myogenin induction is
unaffected by serum conditions, and in agreement with the
work of others indicating that myogenin induction precedes
cell cycle withdrawal in C2 cells (Andre´s and Walsh, 1996).
Myf5/mt Induces Myogenin with High Efficiency at
Low Cell Density
We examined induction of myogenin in U20S cells ex-
pressing different versions of Myf5 (Lindon et al., 2000) by
immunocytochemical analysis. We found that myogenin
was abundantly expressed in clonal lines expressing Myf5/
R93A,L96A (mutated in a “D-box” motif adjacent to the
DNA binding domain, hereafter referred to as Myf5/mt),
with approximately 50% of cells (a 10- to 30-fold increase
over wild-type clones) scoring positive for myogenin expres-
sion after 4 days’ induction of Myf5 at low cell density (Fig.
3 and Table 1). Moreover, increasing cell density did not
favour the induction of myogenin by Myf5/mt (data not
shown), suggesting that the double point mutant
(R93A,L96A) mimics the effect of high cell density. These
results allowed us to think that careful examination of the
functional properties of this mutant might shed light on the
mechanism which ties the permissiveness for myogenin
induction by Myf5 to cell density.
Since this mutant version of Myf5 shows increased mi-
totic stability (Lindon et al., 2000), we examined whether
wild-type Myf5 showed increased mitotic stability in cells
grown at high density. However, we did not detect an
increased mitotic stability of Myf5 at high cell density (data
not shown). Thus, we investigated the possibility that the
gain in function of Myf5/mt with respect to myogenin
induction was due to an effect of this double point mutation
on transactivation functions of Myf5.
Myf5/mt Is a Poor Transactivator of E-Box-
Dependent Reporter Genes
The destruction-box of Myf5 (R93–Q101) identified by
the R93A,L96A double point mutant is immediately adja-
cent to the basic domain. The R93 residue has previously
been implicated in E-box motif binding by Myf5 (Winter et
al., 1992) and we have found that Myf5/mt shows reduced
effectiveness in a myogenic conversion assay (Lindon et al.,
2000). We found that the R93A,L96A double point muta-
ll rights reserved.
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579Cell Density-Dependent Induction of myf4tion causes a 4-fold reduction in DNA binding affinity for
E-box sequences derived either from the Myosin Light
Chain 1/3 promoter (Winter et al., 1992), or from the
myf4/myogenin promoter itself (E1; Salminen et al., 1991),
in an electrophoretic mobility shift assay (data not shown).
We also examined the activity of Myf5/mt in cells by
testing its ability to transactivate muscle-specific promot-
ers in transient transfection assays in 10T1/2 cells. We
found that, in accordance with the relative binding affini-
ties of the different proteins, Myf5/wt was a better transac-
tivator than Myf5/mt of 4R-tk-CAT, an artificial promoter
containing four E-boxes placed in tandem (Weintraub et al.,
1990) (Fig. 4A, upper panel). However a 3.7-kb sequence
containing the mouse myogenin promoter (23.7MyoG-
CAT; Edmondson et al., 1992) was activated to equivalent
levels in the presence of either version of Myf5 (Fig. 4A,
lower panel). It has recently been shown that transactiva-
tion of the myogenin promoter by Myf5 can occur without
occupation of the E1 box, but requires interaction with
MEF2 factor bound to the adjacent MEF2 box (Johanson et
al., 1999). Thus, our result is consistent with the model for
reciprocal recruitment of MEF2 and MRF activities,
through the binding site of either factor, described by
Molkentin et al. (1995), where the R93A,L96A double
mutation compromises DNA binding without affecting
MEF2 interaction. The D76–88 version of Myf5, which
lacks the basic domain, is completely inactive, confirming
FIG. 4. Myf5/R93A, L96A (Myf5/mt) shows loss of function in E
promoter. (A) C3H 10T1/2 cells were transfected with pUHD10–3M
(tetracycline-sensitive transactivator), reporter plasmids 4R-tk-C
presence of tetracycline. Twenty-four hours after transfection, ce
absence of tetracycline. CAT activity was assayed by thin-layer ch
luciferase activity (transfection efficiency) are indicated above sam
(B) UTA6-Myf5/wt and UTA6-Myf5/mt cells (two clones of each) w
or p3F-nlsLACZ-213E, in the presence of tetracycline. p3F-nlsLACZ
a LACZ reporter under control of the E-box-dependent 39 enhanc
unpublished results). Twenty-four hours after transfection, each tra
of tetracycline for a further 48 h. CAT or b-galactosidase activities
to Myf5. Results were averaged across clones expressing the sam
experiments.that Myf5/mt is a specific transactivator of 23.7MyoG-
© 2001 Elsevier Science. ACAT. We also note that whereas activation of the 4R-tk-
CAT reporter is strictly dependent on withdrawal of tetra-
cycline from the culture medium, 23.7MyoG-CAT is
expressed equally well in the presence or absence of tetra-
cycline. We believe that this is the result of “leakage” of
tetracycline-mediated repression of the nonintegrated
Myf5-expressing plasmids, and suggests that transactiva-
tion of the myogenin promoter by Myf5 (wt or mt) is highly
efficient compared to that of the artificial E-box-containing
promoter.
In addition, we transfected UTA6-derived cell lines with
various reporter plasmids. We compared the inducibility of
different constructs (i.e., the fold increase in their expres-
sion upon removal of tetracycline from the culture me-
dium) in cells expressing each version of Myf5 (wt or mt,
Fig. 4B). This analysis confirms that in UTA6-Myf5 cell
lines the inducibility of the myogenin promoter construct
in cells expressing Myf5/mt is comparable to that seen in
cells expressing Myf5/wt, whereas inducibility of E-box-
dependent promoters (4R-tk-CAT, p3F-nlsLACZ-213E) is
severely impaired.
We have also tested the activity of a human myogenin/
myf4 promoter construct (21124myf4-CAT; Salminen et
al., 1991) in UTA6-Myf5/wt and UTA6-Myf5/mt cells,
finding no significant difference in promoter activity be-
tween these cells (data not shown). This agrees with pub-
lished studies where the behaviour of endogenous or trans-
transactivation, but is competent to transactivate the myogenin
expression plasmids (described in Lindon et al., 2000), pUHD15–1
or 23.7MyoG-CAT and control plasmid pSV-luciferase, in the
ere washed then incubated for a further 48 h in the presence or
atography of reaction products. Quantified activities corrected for
This experiment was carried out three times with similar results.
transfected with reporter constructs 4R-tk-CAT, 23.7MyoG-CAT,
E is derived from p3F-nlsLACZ-2E (Kelly et al., 1995), and encodes
om the MLC1F/3F locus (P. Zammit, R. Kelly, M. Buckingham,
ted population was passaged and plated in the presence or absence
used to calculate the fold-induction of each construct in response
sion of Myf5. Similar results were obtained in four independent-box
yf5
AT,
lls w
rom
ples.
ere
-213
er fr
nsfec
werefected human and mouse myogenin promoters appears to be
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580 Lindon et al.similar (Buchberger et al., 1994; Johanson et al., 1999;
Molkentin et al., 1995). We conclude that neither the
mouse nor the human myogenin promoter is more strongly
transactivated by Myf/mt than by Myf/wt.
FIG. 5. Cells expressing Myf5/wt repress induction of myogenin in
UTA6 cells or UTA6-Myf5/wt cells and plated at low cell density
immunocytochemistry, and counter-stained with DAPI. One fiel
expressing cells—is shown. The statistics shown represent the tota
fields; the mean and standard deviations were calculated from two
FIG. 6. Overexpression of Myf5 in C2 myoblast cells leads to diff
which Myf5 is under control of ecdysone (see Materials and Met
myogenin or Myf5 and Troponin T, and analysed by confocal micr
expression in our hands gives target gene expression in only subpop
-negative cells within the same fields, for expression of myogenin o
(mean plus standard deviations) were calculated from three indepeIt seems unlikely that specific DNA elements outside of
© 2001 Elsevier Science. Athe 23.7-kb promoter are required for the differential activ-
ity of Myf5/wt and Myf5/mt on the endogenous myogenin
promoter since 2184 bp of myogenin promoter is sufficient
to drive correct temporal and spatial expression of a trans-
ltured cells. UTA6-Myf5/mt cells were mixed in a ratio of 1:9 with
ter 4 days, cells were fixed, analysed for myogenin expression by
m each type of culture—showing typical clusters of myogenin-
ber of myogenin-positive cells counted over 10 randomly chosen
h counts from each of two independent experiments.
iation in the absence of myogenin expression. Clonal cell lines in
) were induced for 4 days, costained for expression of Myf5 and
py. Representative images are shown. This system for conditional
ons of clonally derived cells, therefore we scored Myf5-positive and
ponin T. The percentages of cells scoring positive for each marker
t experiments.cocu
. Af
d fro
l num
suc
erent
hods
osco
ulati
r Trogene during myogenesis in the mouse (Cheng et al., 1993).
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Myf5/mt to induce myogenin correlates with decreased
affinity for E-box sequences.
Myf5 Represses Induction of Myogenin Expression
in a Non-cell-Autonomous Manner
To examine the hypothesis—arising from our observation
that loss of E-box affinity favours myogenin induction—
that Myf5 acts as a repressor of the myogenin promoter at
low cell density, we transiently transfected UTA6-Myf5/mt
cells with Myf5/wt to test whether the wild-type protein
could block myogenin induction by Myf5/mt. To our sur-
prise, we found that transfection with Myf5/wt dramati-
cally reduced induction of myogenin in all UTA6-Myf5/mt
cells in the culture dish, and not only in those scored as
transfected cells (data not shown). Since we could not
eliminate the possibility that all of the cells were trans-
fected, albeit at levels indetectable by immunofluores-
cence, we chose to verify this observation by coculture of
UTA6-Myf5/wt and UTA6-Myf5/mt cells. UTA6-Myf5/mt
cells were mixed (1:9) with UTA6-Myf5/wt cells, or paren-
tal UTA6 cells as control, and plated at low cell density.
Cocultured cells were stained for myogenin expression after
4 days. We found a reduction both in the frequency of
myogenin-positive cells, and in the intensity of staining for
myogenin expression, in the cocultures containing UTA6-
Myf5/wt cells (Fig. 5), when compared to those containing
parental UTA6 cells. Thus, the presence of an excess of
Myf5/wt-expressing cells diminishes the ability of cocul-
tured Myf5/mt-expressing cells to induce myogenin. This
indicates that the inhibition of myogenin inducibility
by wild-type Myf5 can occur in a non-cell-autonomous
TABLE 1
Expression of Endogenous Myogenin in U20S-Derived Cell Lines
Protein expressed Clone % Myogenin 1 cells
MyoD M2 18
Myf5/wild-type A2 1.9
A1 0.6
A5 3.0
Myf5/R93A, L96A R4 39
R5 55
Myf5/S158A S1 3.4
Note. Clonal cell lines were plated at 4 3 103 cells/cm2 in 10%
FCS in the absence of tetracycline. Cells were fixed and stained for
myogenin expression after 4 days. The total number of myogenin-
positive cells was counted in 10 randomly chosen fields, and
calculated as the percentage of total number of cells in those 10
fields.manner.
© 2001 Elsevier Science. ADifferentiation of Myoblast Cells Overexpressing
Myf5 Occurs in the Absence of Myogenin
Expression
We were concerned that the differentiation of Myf5-
expressing U2OS cells might not constitute a valid myo-
genic model, since the differentiation of Myf5-expressing
cells without expression of myogenin (Fig. 1) is contrary to
existing models of myogenesis, in which expression of
myogenin is an obligatory step for terminal differentiation.
Therefore, we examined expression of myogenic markers in
mouse C2 myoblast cells overexpressing Myf5 under con-
trol of an ecdysone-regulated promoter. We found that
strong expression of Myf5 appeared to favour expression of
Troponin T, whilst rendering the cells less likely to express
myogenin (Fig. 6). We conclude that, as in UTA6-Myf5
cells, Myf5 overexpression in myoblasts does not induce
expression of myogenin, and that artificially elevated levels
of Myf5 can support myogenic differentiation in the ab-
sence of myogenin expression. We note that in this experi-
ment (unlike that shown in Fig. 5) any effect of Myf5 on
myogenin expression would appear to be cell-autonomous.
However, in contrast to the experiment shown in Fig. 5,
where the population of Myf5-expressing cells is in excess
over the cells in which we see myogenin expression re-
pressed, in Fig. 6 only a small fraction of cells is Myf5-
positive. Coculture of UTA6-Myf5wt and UTA6-Myf5mt
cells in a similar ratio did not give rise to any effect on
myogenin expression discernible in our assay. Thus, we
suggest that the population of Myf5-positive cells in Fig. 6
is too low to give rise to the non-cell-autonomous effect
detected in Fig. 5.
Finally, we have examined Myf5 and myogenin expres-
sion in MyoD2/2 myoblasts (Montarras et al., 2000). We find
that Myf5 expression is strongly enhanced in these cells
compared to MyoD1/2 myoblasts, whilst there is a 10-fold
reduction in the number of cells scoring positive for myo-
genin expression (D.M., unpublished results). Thus, the
expression pattern of the MRFs in this “ex vivo ” cell
system supports a model in which, under equivalent con-
ditions, myogenin is induced by MyoD but not by Myf5.
DISCUSSION
Expression of myogenin is the earliest known sign of
commitment of myogenic cells to terminal differentiation
(Andre´s and Walsh, 1996), and is associated with induction
of the cdk inhibitors p21CIP1 (Andre´s and Walsh, 1996;
Zhang et al., 1999b) and p57KIP2 (Zhang et al., 1999b). The
myogenin promoter has been demonstrated to be a direct
target of MyoD (Gerber et al., 1997; Hollenberg et al., 1993).
Similar experiments have shown that Myf5 also can induce
myogenin transcription in the absence of protein synthesis
(Buchberger et al., 1994), although this conclusion relies on
nonquanitative detection of myogenin transcripts by RT-
PCR, and thus does not permit comparison of the relative
efficiencies of Myf5 and MyoD. Finally, gene ablation
ll rights reserved.
582 Lindon et al.experiments in vivo have provided genetic evidence that
myogenin expression requires either Myf5 or MyoD, sug-
gesting that both factors share the capacity to positively
regulate myogenin expression. In our studies, myogenic
conversion is examined in cell lines where Myf5 expression
is conditional and occurs without concomitant MyoD ex-
pression. They reveal that, under conditions where Myf5
and MyoD are able to transactivate differentiation-specific
promoters, only MyoD, and not Myf5, efficiently induces
expression of the myogenin gene. Similarly, in mouse
myocytes, overexpression of Myf5 can drive terminal dif-
ferentiation without inducing myogenin. Thus, Myf5 un-
couples the regulation of myogenin induction from that of
the E-box-dependent muscle-specific expression pro-
gramme. Expression of myogenin is apparently not required
for myogenic conversion of U20S cells upon Myf5 induc-
tion, nor for terminal differentiation of myocytes in re-
sponse to Myf5. Probably overexpression of Myf5 bypasses
a requirement for normally crucial intermediates through
the direct activity of Myf5 on muscle-specific promoters.
We have found that myogenin induction by Myf5 re-
quires high cell density. That high cell density favours
growth arrest and/or depletion of serum components can-
not explain why it favours myogenin expression since: (1)
Cell cycle withdrawal is not associated with expression of
myogenin in these cells; (2) Favouring cell cycle withdrawal
by serum starvation—which increases expression of the
differentiation marker Troponin T—does not favour myo-
genin induction. Since the ability of Myf5 to induce expres-
sion of Troponin T is not attenuated at low cell density the
effect of cell density is not a general regulation of Myf5
activity, but implies the existence of a specific mechanism
to limit the activation of the myogenin promoter by Myf5
at low cell density. We believe that it is cell density, and not
cell–cell contact, which is permissive for expression of
myogenin in our myogenic system, since the distribution of
myogenin-positive cells identified by immunofluorescence
on fixed cultures is not influenced by local variations in cell
density. We note that our immunocytochemical data ap-
pear to support a stochastic model (Fiering et al., 2000) for
activation of the myogenin promoter in these cells.
By chance, we have found that cell lines previously
derived in the laboratory, which express a mutant version of
Myf5 (UTA6-Myf5/R93A,L96A; Lindon et al., 2000), ex-
hibit myogenin induction irrespective of cell density. This
mutant version of Myf5 (Myf5/mt) appears identical to the
wild-type protein in its ability to transactivate reporter
constructs driven by the myogenin promoter in transient
transfection assays, but differs from the wild-type protein in
at least two properties: improved mitotic stability and
reduced E-box binding activity, giving rise to poor transac-
tivation of E-box-dependent reporters. We have subse-
quently found that cells become less sensitive to Myf5/mt-
mediated induction of myogenin (normally highly efficient
at low density) when cocultured with cells expressing
wild-type Myf5. That is, at low cell density there is non-
cell-autonomous repressive effect of Myf5 on myogenin
© 2001 Elsevier Science. Ainduction. For this reason, we favour the interpretation that
the efficient induction of myogenin expression in UTA6-
Myf5/mt cells is due to the poor E-box binding activity of
this version of Myf5, which reduces the production of a
factor that inhibits myogenin expression at low cell den-
sity. However, we have not excluded the possibility that
there is an altered interaction with another binding
partner—such as HDAC1 (Mal et al., 2001)—which is of
relevance to the observed properties of Myf5/mt. Moreover,
since we have not succeeded in regulating myogenin ex-
pression by means of medium conditioned by wild-type
cells, the nature of a putative repressor remains unclear.
Myogenin induction in in vitro models of muscle differ-
entiation is associated with loss of Myf5 expression (Carnac
et al., 2000; Kitzmann et al., 1998; Lindon et al., 1998;
Mangiacapra et al., 1992; Yoshida et al., 1998), whilst Myf5
expression following growth arrest is restricted to a quies-
cent, nondifferentiated (that is, myogenin-negative) popula-
tion of “reserve” cells (Carnac et al., 2000; Yoshida et al.,
1998). Moreover, we have recently found that myogenin is
precociously expressed in myoblasts derived from myf52/2
mice, which show reduced proliferation and premature
differentiation compared to wild-type myoblasts (Montar-
ras et al., 2000). Thus, in several other myogenic systems,
Myf5 appears to exert a negative effect on myogenin expres-
sion and terminal differentiation. The repression mecha-
nism controlled by Myf5 would contribute to delay induc-
tion of myogenin whilst the pool of precursor myoblasts
expands to attain a cell number appropriate for the onset of
terminal differentiation. Interestingly, while Myf5 supports
a nearly normal myogenesis in MyoD2/2 animals, a gene
knock-in of myogenin into the myf5 locus in this genetic
background leads to profoundly reduced skeletal muscle
formation (Wang and Jaenisch, 1997). Widely interpreted to
mean that Myf5 has functions (such as chromatin remod-
elling) not shared by myogenin and required for recruitment
of precursor cells, this result could also support our conten-
tion that delayed expression of myogenin is required for
establishment of the precursor pool of cells.
Why does MyoD induce myogenin expression more effi-
ciently than Myf5? Our preliminary results suggest that
coculture of UTA6-MyoD cells and UTA6-Myf5/mt cells
has no effect on myogenin induction in the latter, and that
coculture of UTA6-MyoD cells with UTA6-Myf5/wt leads
to some repression of myogenin induction in UTA6-MyoD
cells. Thus, we believe that the difference in efficiency of
myogenin induction by Myf5 and MyoD which we see in
our myogenic system reflects a difference in their ability to
induce a myogenin repressor. This myogenic system may
allow identification of the distinct targets of Myf5 and
MyoD in proliferating cells. We predict that one of these
targets will be a secreted factor expressed in E-box-
dependent fashion in response to Myf5 but not MyoD. This
factor should be tested as a candidate repressor of myogenin
expression.
ll rights reserved.
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